6- amino- 1- hydroxyhexane- 1,1- diphosphonate

01/01/2022 - "Benefits on pain, clinical and functional measures were maintained and further improved over 12 months in most patients treated with neridronate administered either IM or IV. In IM-treated patients, the percentage of those defined as responders (VAS score reduction ≥ 50%) progressively increased up to day 360 to 32 of 35 patients (91.4%). "
09/01/2021 - "The patient was treated with intramuscular neridronate, which resulted in significant pain relief and improved his quality of life. "
01/01/2021 - "Whereas no difference was observed for QoL measures using the SF-36 questionnaire, three of the four pain variables using the McGill Pain Questionnaire improved significantly in the neridronate group. "
10/01/2015 - "The aim of this randomized, double-blind, placebo-controlled study was to assess the efficacy of i.v. neridronate in controlling pain in patients with acute painful knee OA. "
01/01/2022 - "In patients with acute CRPS-1, the benefit in pain, clinical, and functional measures observed a few weeks after neridronate treatment administered either IM or IV is maintained and further improved over 12 months. "

10/06/2022 - "Intravenous neridronate is effective in regional migratory osteoporosis."
03/01/2007 - "Can neridronate be effective in the treatment of osteoporosis in hypogonadic men?"
09/01/2022 - "Efficacy of intravenous neridronate in transient osteoporosis of the hip."
05/30/2023 - "We searched PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL) for reports published until August 31, 2021, related to neridronate and osteoporosis. "
05/30/2023 - "We aimed to conduct a meta-analysis of the effect of neridronate on the treatment of osteoporosis. "

01/01/2021 - "The study was aimed at monitoring vertebral bodies changes with the use of Vertebral Fracture Assessment (VFA) in children and adolescents affected by osteogenesis imperfecta (OI) during treatment with intravenous neridronate. "
10/01/2017 - "The present study assessed the long-term efficacy and safety of intravenous (i.v.) neridronate in children and adolescents affected by osteogenesis imperfecta (OI). "
10/01/2017 - "Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study."
01/01/2017 - "The aim of this study was to assess the long-term efficacy and safety of i.v. neridronate in the treatment of osteogenesis imperfecta (OI). "
01/01/2017 - "Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study."

10/01/2009 - "In Paget's disease of bone, 200 mg intravenous neridronic acid is associated with a 65% rate of full remission and a biochemical response (decrease of > 75% of bone turnover markers) in 95% of the patients. "
12/01/2021 - "This is a 48 months observational, descriptive and prospective study on patients with active Paget's disease of bone treated with intravenous Neridronate. "
03/01/2011 - "Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone."
01/01/2013 - "Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget's disease of bone (PDB). "
05/01/2017 - "Neridronate is an amino-bisphosphonate, licensed in Italy for the treatment of OI and Paget's disease of bone. "

05/01/2017 - "Neridronate appears to increase Bone Mineral Density (BMD) in adults with OI and reduces bone resorption by inhibition of osteoclastic activity. "
01/01/2007 - "This may encourage the use of neridronic acid to reduce bone resorption in the therapy of demineralizing metabolic bone disorders."
07/01/2012 - "In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. "
06/01/2002 - "Single infusion of neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthritis: effects on disease activity and bone resorption markers."
01/01/2007 - "The tissue-specific targeting of neridronic acid to bone mineral suggests that it may inhibit bone resorption by direct effects on osteoclasts or other bone cells in the immediate microenvironment of the osteoclasts. "